Received Jul 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | LB93L | — |
4 month old female patient received a dose of Menveo 1 vial presentation.; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 4-month-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number LB93L, expiry date 30-JUN-2025) for prophylaxis. On 30-JUN-2025, the patient received the 1st dose of Menveo. On 30-JUN-2025, an unknown time after receiving Menveo, the patient experienced inappropriate age at vaccine administration (Verbatim: 4 month old female patient received a dose of Menveo 1 vial presentation.). The outcome of the inappropriate age at vaccine administration was not applicable. Additional Information: GSK Receipt Date: 02-JUL-2025 The charge nurse called to ask if a 4 months old female patient received the 1-vial presentation of Menveo on 30th June 2025 which led to inappropriate age at vaccine administration. The reporter asked was there anything specific to do next. The reporter also asked that did they continue with the 2-vial to complete the series.